Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase
Nucleic Acid Therapeutics (NATs), including siRNAs and AntiSense Oligonucleotides (ASOs), have great potential to drug the undruggable genome. Targeting siRNAs and ASOs to specific cell types of interest has driven dramatic improvement in efficacy and reduction in toxicity. Indeed, conjugation of tr...
Main Authors: | Ian J. Huggins, Carlos A. Medina, Aaron D. Springer, Arjen van den Berg, Satish Jadhav, Xianshu Cui, Steven F. Dowdy |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-09-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/24/18/3287 |
Similar Items
-
Lipid and Peptide-Oligonucleotide Conjugates for Therapeutic Purposes: From Simple Hybrids to Complex Multifunctional Assemblies
by: Carme Fàbrega, et al.
Published: (2023-01-01) -
Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
by: Julien Dugal-Tessier, et al.
Published: (2021-02-01) -
Delivery of Oligonucleotides Using a Self-Degradable Lipid-Like Material
by: Hiroki Tanaka, et al.
Published: (2021-04-01) -
Chemistry of Therapeutic Oligonucleotides That Drives Interactions with Biomolecules
by: Chisato Terada, et al.
Published: (2022-11-01) -
Recent Advances in Oligonucleotide Therapeutics in Oncology
by: Haoyu Xiong, et al.
Published: (2021-03-01)